ImmunoGen Shares Rise 25% on FY/19 Financial Results and Clinical Pipeline Updates

  ()
Shares of ImmunoGen Inc. reached a new 52-week intraday high price after the company announced FY/19 financial results and reported on recent developments including the completion of a $97.6 million capital raise in January 2020. read more >

vTv Therapeutics' Shares Open 80% Higher on Phase 2 Type 1 Diabetes Trial Data

  ()
Shares of vTv Therapeutics traded 50% higher after the company reported positive results from Part 2 of the Phase 2 Simplici-T1 Study of TTP399 used in the treatment of patients with type 1 diabetes. read more >

Biopharma Has Three 2020 Shots on Goal in Pediatric Liver Diseases

Research Report
  ()
The events in that trio are presented in a ROTH Capital Partners report. read more >
News Update

Telehealth Solutions Firm Gains Further Customer Traction in Texas

News Update
  ()
With the added clients, the company will expand into two more clinical realms. read more >

Myriad Genetics Shares Fall 30% on Q2 Earnings and Executive Leadership Change

  ()
Shares of Myriad Genetics traded 30% lower after the firm released Q2/20 earnings and announced the appointment of a new interim CEO. read more >

Cortexyme Secures $125M Private Placement Capital to Advance Clinical Development

  ()
Shares of Cortexyme Inc. traded 20% higher after the company reported that it secured an additional $125M in capital from a private placement. The firm intends to use the proceeds to fund current Alzheimer's clinical trials and ongoing operations. read more >
News Update

MedTech Company Launches Direct to Consumer Telemedicine App

News Update
  ()
The product is initially available to residents of British Columbia. read more >

Understanding Fortress Biotech

Contributed Opinion
  ()
Daniel Carlson of Tailwinds Research takes a close look at what he calls a "great value opportunity," with a focus on subsidiary Avenue Therapeutics. read more >

Vivus Shares Climb 50% Higher on sNDA Approval for Exocrine Pancreatic Insufficiency Drug

  ()
Shares of Vivus traded higher after the FDA approved the company's supplemental New Drug Application for an improved formulation of PANCREAZEŽ (pancrelipase) for use in the treatment of exocrine pancreatic insufficiency due to cystic fibrosis and other conditions. read more >
News Update

Rapidly Growing Healthcare Tech Firm Appoints President

News Update
  ()
The appointed physician will be tasked with developing global business for the company. read more >

Expert Investing Ideas

"DRRX earned a $10M milestone payment from Gilead."

–Ed Arce, H.C. Wainwright & Co.


"The market for DRRX's POSIMIR could be substantial."

–Brian Marckx, Zacks Small-Cap Research


Learn More about Which Online Broker is Right for You?

Get Our Streetwise Reports Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe
NASDAQ Biotech ARCA Pharmaceutical

Insmed Shares Trade 40% Higher on Phase 2 Top-Line Bronchiectasis Trial Data

  ()
Insmed Inc.'s shares traded higher after the company reported positive top-line results from its Phase 2 WILLOW Study of INS1007 in patients with non-cystic fibrosis bronchiectasis. read more >

Syndax Pharma Shares Rise on $35M Capital Raise, Credit Line and Positive Phase 1/2 Leukemia Trial Results

  ()
Syndax Pharmaceuticals' shares traded 30% higher after the company reported it expects to raise $35 million from a common stock offering from five institutional investors and secured a $30 million non-dilutive term loan facility. read more >

'Stay Tuned for Data' from Regenerative Medicine Firm with 'Blockbuster Opportunity'

Research Report
  ()
The compelling aspects of this life sciences story are presented in a Dawson James report. read more >

Arcadia Ropes in $3 Million in GoodHemp Seed Purchase Orders Within 50 Days of Product Launch

  ()
Arcadia Biosciences shares traded 25% higher after reporting that it secured $3 million in pre-season GoodHemp seed purchase commitments in just 50 days after launching the product. read more >